Health Canada Approves JERAYGO for Resistant Hypertension with Double-Digit SBP Reductions
Health Canada approved JERAYGO (aprocitentan), the first endothelin receptor antagonist for adult resistant hypertension in combination with ≥3 antihypertensives, at a recommended 12.5 mg once-daily dose (up-titrable to 25 mg). PRECISION trial in 730 patients showed double-digit systolic reductions at Week 4 with both 12.5 mg and 25 mg doses.
Related News
EXR
Extra Space Storage Adds Retail and Tech Executives with 850-Unit Chain, Ex-Matterport CEO to Board
EXR•
NVDA
Nvidia Tops $91B Sales Forecast, Boosts Dividend and Buyback Program
NVDA•
NVDA
Nvidia posts $81.6bn Q1 revenue, raises dividend 25-fold and authorizes $80bn buyback
NVDA•
NVDA
Nvidia posts US$81.6B Q1 revenue, forecasts US$91B for Q2
NVDA•
AAPL
Apple App Store Blocks 1 Billion Fake Accounts, Prevents $2.2B Fraud
AAPL•
Sources
GGG